Flexible dose of semaglutide reduces early discontinuation while maintaining comparable outcomes in obese patients: FLEX ‐ SEMA 2.4 mg, an Italian real‐world study
Authors' conclusion
This real-world analysis provides valuable insights into the use of semaglutide in routine clinical practice, confirming a favourable efficacy profile with flexible dosing patterns.
Study context
- Population
- Obese patients treated with weekly injectable semaglutide, Italy; 80% women, mean age 51.12, median body mass index (BMI) 35.56 kg/m²
- Participants
- 111 patients
- Outcome
- Weight loss categories
Methodological detailsreal-world
- Real-world
Main finding
As reported in the abstract
Weight loss ≥5%
23.5%
Weight loss ≥10%
34.6%
Weight loss ≥15%
30.8%
Weight loss ≥20%
11.1%
Observational data: associations, not effects.
Further findings
Dosing
- Initiated at 0.25 mg
- 81.1%
- Increased to 1 mg after 3 months
- 72.1%
- On 0.5 mg at 6 months
- 2%
- On 1 mg at 6 months
- 40%
- On 2.4 mg at 6 months
- 26%
Early discontinuation
- At 3 months
- 6.3%
- At 6 months (cost, adverse events, inefficacy)
- 10.5%
Safety
- Adverse events at 3 months
- 56.8%
- Discontinuation due to adverse events by 3 months
- 3 patients
- Adverse events at 6 months
- 32.6%
- Discontinuation due to adverse events by 6 months
- 2 patients
Original publication
Flexible dose of semaglutide reduces early discontinuation while maintaining comparable outcomes in obese patients: FLEX ‐ SEMA 2.4 mg, an Italian real‐world study. Diabetes Obes Metab. Published 23 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →